Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049361 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049361 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences.
The verdict
NCT00049361, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining whole-brain radiation therapy with thalidomide and temozolomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining whole-brain radiation therapy with thalidomide and temozolomide in treating patients who have newly diagnosed brain metastases.
Interventions
- DRUG temozolomide
- RADIATION radiation therapy
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-01-01 |
| Est. Completion | 2004-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049361
The ClinicalTrials.gov registry entry for NCT00049361 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which temozolomide is the first listed.
NCT00049361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049361 about?
NCT00049361 is a clinical study titled "Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining whole-brain radiation ther...
What is the current status of trial NCT00049361?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-01-01. Estimated completion is 2004-12-07.
What interventions are being tested in trial NCT00049361?
The interventions under investigation include: temozolomide (DRUG), radiation therapy (RADIATION), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00049361?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.